Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,844
  • Shares Outstanding, K 21,040
  • Annual Sales, $ 6,830 K
  • Annual Income, $ -18,590 K
  • 60-Month Beta 1.90
  • Price/Sales 2.06
  • Price/Cash Flow N/A
  • Price/Book 0.94
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.04
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/14/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.24
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4720 +54.64%
on 05/01/20
0.8799 -17.05%
on 05/12/20
+0.2144 (+41.59%)
since 04/28/20
3-Month
0.4300 +69.74%
on 03/23/20
0.8799 -17.05%
on 05/12/20
-0.0128 (-1.72%)
since 02/28/20
52-Week
0.4300 +69.74%
on 03/23/20
1.7400 -58.05%
on 01/09/20
-0.5301 (-42.07%)
since 05/28/19

Most Recent Stories

More News
After Yesterday's Decline of 12.88%, Regulus Therapeu Offers Investors Better Value

Regulus Therapeu (NASDAQ:RGLS) traded in a range yesterday that spanned from a low of $0.55 to a high of $0.63. Yesterday, the shares fell 12.9%, which took the trading range below the 3-day low of $0.56...

RGLS : 0.7398 (+12.43%)
Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates

, /PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial...

RGLS : 0.7398 (+12.43%)
Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?

Regulus (RGLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RGLS : 0.7398 (+12.43%)
Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial...

RGLS : 0.7398 (+12.43%)
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RGLS : 0.7398 (+12.43%)
Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it initiated dosing of the...

RGLS : 0.7398 (+12.43%)
Regulus Therapeu Set to Possibly Rebound After Yesterday's Selloff of 11.59%

Regulus Therapeu (NASDAQ:RGLS) traded in a range yesterday that spanned from a low of $0.60 to a high of $0.70. Yesterday, the shares fell 11.6%, which took the trading range below the 3-day low of $0.69...

RGLS : 0.7398 (+12.43%)
Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration...

RGLS : 0.7398 (+12.43%)
Regulus Therapeutics to Present at the Stifel Healthcare Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and...

RGLS : 0.7398 (+12.43%)
Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 10.34% and -10.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

RGLS : 0.7398 (+12.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade RGLS with:

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

2nd Resistance Point 0.7127
1st Resistance Point 0.6853
Last Price 0.7398
1st Support Level 0.6253
2nd Support Level 0.5927

See More

52-Week High 1.7400
Fibonacci 61.8% 1.2396
Fibonacci 50% 1.0850
Fibonacci 38.2% 0.9304
Last Price 0.7398
52-Week Low 0.4300

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar